EZH2 and Burkitt lymphoma: DZnep effectively depletes cellular levels of EZH2, inhibits tri-methylation of Histone H3 at lysine 27, and induces cell apoptosis in a variety of cancerous contexts [115–118], including Burkitt lymphoma [119], ALL [120], and NKTL [52].